Risk stratification of oesophageal squamous cell carcinoma using change in total lesion glycolysis and number of PET-positive lymph nodes
Menée auprès de 226 patients atteints d'un carcinome épidermoïde de la tête et du cou ayant bénéficié d'une tomographie numérique par émission de positrons avant et après une chimiothérapie néo-adjuvante, cette étude détermine les valeurs seuil optimales de différents paramètres tomographiques (SUVmax, volume métabolique tumoral et taux de réduction de la glycolyse totale de la lésion) puis évalue l'association entre ces paramètres, le nombre de ganglions lymphatiques atteints d'après la tomographie et la survie des patients
Background : The efficacy of neoadjuvant chemotherapy (NACT) correlates with patient survival in oesophageal squamous cell carcinoma (OSCC), but optimal evaluation of the treatment response based on PET-CT parameters has not been established.
Methods : We analysed 226 OSCC patients who underwent PET-CT before and after NACT followed by surgery. We assessed SUVmax, metabolic tumour volume (MTV), and total lesion glycolysis (TLG) for the primary tumour and the number of PET-positive lymph nodes before and after NACT to predict patient survival.
Results : In a stepwise analysis, we defined 60%, 80%, and 80% as the optimal cut-off values for SUVmax, MTV, and TLG reduction, respectively, to distinguish responders and non-responders to NACT. In the ROC analysis, the TLG reduction rate was the best predictor of recurrence among PET-CT parameters. The TLG responders achieved significantly more favourable prognoses than non-responders (2-year progression-free survival [PFS] rate: 64.1% vs. 38.5%; P = 0.0001). TLG reduction rate (HR 2.58; 95% CI 1.16–5.73) and the number of PET-positive lymph nodes after NACT (HR 1.79; 95% CI 1.04–3.08) were significant independent prognostic factors.
Conclusions : TLG reduction is the best predictor of prognosis. Preoperative PET-CT evaluation of both the primary tumour and lymph nodes could accurately stratify risk in OSCC patients.
British Journal of Cancer , article en libre accès, 2023